Cellen / Leva Clinic

What it is

Leva Clinic is a UK digital medical cannabis clinic that launched in 2019 as the patient-facing service of Cellen Health, a London-based health technology company ^[1][2]. It was set up to offer remote consultations with specialist doctors who could issue private prescriptions for unlicensed cannabis-based products for medicinal use (CBPMs), following the November 2018 rescheduling that allowed specialist UK doctors to prescribe these products ^[3].

Like other UK cannabis clinics, Leva does not dispense cannabis itself in a recreational sense. It operates as a private medical service: patients pay for consultations, and prescriptions are dispatched through licensed pharmacies that import or supply CBPMs under Home Office and MHRA rules ^[3][4]. The clinic's positioning was explicitly telehealth-first, with video consultations rather than in-person clinics.

Ownership and corporate structure

Public reporting from the clinic's launch period describes Leva Clinic as a service of Cellen Health, part of the broader Cellen Life Sciences group based in London ^[1][2]. Cellen Health raised early-stage funding in 2019 reported at around US$3.3 million to launch the clinic ^[1]. Beyond that, detailed ownership, shareholder, and current corporate structure information is not consistently public, and any claims about parent companies, mergers, or rebrands should be checked against the UK Companies House register before being relied on ^[5]. Weak / limited

This is a common pattern in the UK medical cannabis sector: clinics, holding companies and pharmacy partners are often separate legal entities with overlapping branding, and structures change as the market consolidates.

Market and category focus

Leva sits in the UK private medical cannabis clinic category, alongside operators such as Sapphire Medical Clinics, Curaleaf Clinic (formerly Sapphire), Mamedica, Releaf and others. These clinics serve patients who have not responded to at least two licensed treatments for a given condition — the threshold expected by specialist prescribers under General Medical Council and NICE-aligned guidance ^[3][6].

Typical conditions treated across the UK clinic sector include chronic pain, anxiety-related conditions, PTSD, multiple sclerosis–related spasticity, treatment-resistant epilepsy, and chemotherapy-induced nausea. NICE has consistently noted that the evidence base for most of these indications is limited, and recommends cannabis-based medicines only in narrow circumstances ^[6]. Strong evidence Clinics including Leva have publicly framed themselves as gathering real-world evidence to fill that gap, though independent peer-reviewed outcomes data specific to Leva is limited.

Notable services

Leva's core service is a remote specialist consultation, followed (if appropriate) by a private prescription for a CBPM — typically dried cannabis flower or oil products. The clinic has at various points published information about a multidisciplinary team including doctors, pharmacists and pain specialists ^[2]. It is described in trade press as one of the early UK clinics to register patients with the now-discontinued Project Twenty21 observational study and similar real-world evidence projects ^[7]. Weak / limited

This profile does not endorse any specific Leva product, formulation or treatment pathway. Cannabis-based medicines in the UK are unlicensed specials, meaning the prescribing doctor — not the manufacturer — carries clinical responsibility, and product availability changes frequently.

Reputation, regulation and controversies

UK private clinics offering medical cannabis are subject to oversight by the Care Quality Commission (CQC) in England, the General Medical Council for individual doctors, and the MHRA for product-related issues ^[4][8]. Patients can check a clinic's CQC inspection rating directly ^[8]. Leva has been covered in mainstream and trade press since launch ^[1][2][7], but we have not identified high-quality, independent peer-reviewed evaluations of its clinical outcomes.

We are not aware of formal enforcement action against Leva at the time of last check, but absence of public action is not the same as endorsement. The broader UK cannabis clinic sector has faced criticism over advertising practices, with the Advertising Standards Authority repeatedly ruling against cannabis-related health claims by various operators ^[9]. Readers should not assume any specific clinic is exempt from these concerns without checking current rulings.

Availability and legal market notes

Leva, like other UK clinics, can only legally serve patients in the UK and operates within the Home Office's framework for Schedule 2 controlled drugs ^[3]. Prescriptions are issued by GMC-registered specialists on the Specialist Register; GPs cannot initiate these prescriptions. Costs are paid privately — NHS prescribing of cannabis-based medicines remains extremely rare and is essentially limited to Epidyolex, Sativex, and nabilone within their licensed indications ^[3][6].

Product supply depends on licensed importers and specials pharmacies, and individual products can become unavailable at short notice. Patients travelling abroad with prescribed cannabis face country-specific restrictions and should consult Home Office and destination-country guidance.

What to verify before relying on brand claims

Before engaging with Leva — or any UK cannabis clinic — readers should independently verify:

• Current operating status and CQC rating via the CQC public register ^[8].
• Company status and ownership via Companies House ^[5].
• The prescribing doctor's GMC registration and Specialist Register entry ^[4].
• Pharmacy partner registration with the General Pharmaceutical Council.
• Whether your condition and prior treatment history meet the published prescribing thresholds ^[6].
• Total realistic cost including consultations, follow-ups and ongoing prescriptions, not just the headline initial fee.

Any marketing claim about success rates, patient numbers, product safety, exclusivity, or being 'the leading' UK clinic should be treated as marketing unless backed by an independent, dated source. No data

Profile last checked: 2024. Operational details in this market change quickly; confirm current information directly with the clinic and the regulators before making decisions.

Sources

How this page was made